|
NCT06425302
|
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2)
|
En recrutement
|
11 avril 2025
|
|
NCT05514054
|
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence (EMBER-4)
|
En recrutement
|
11 avril 2025
|
|
NCT05895344
|
Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma (COG-PROTON-01)
|
En recrutement
|
10 avril 2025
|
|
NCT02884375
|
Elderly Cancer Patient: ELCAPA Cohort Survey (ELCAPA)
|
En recrutement
|
10 avril 2025
|
|
NCT05697146
|
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study (RosaLEE)
|
En recrutement
|
10 avril 2025
|
|
NCT05630105
|
National Cohort of Patients With Cowden's Disease and With a Constitutional Alteration of the PTEN Gene for the Prospective Assessment of the Risk of Cancer. (COCO)
|
En recrutement
|
10 avril 2025
|
|
NCT05440331
|
Morbidity and Mortality in Operating Room: Surgery and Standardized Communication (HIATUS)
|
En recrutement
|
10 avril 2025
|
|
NCT05945732
|
A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-low Europe)
|
En recrutement
|
10 avril 2025
|
|
NCT01689584
|
Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling (COVAR)
|
En recrutement
|
10 avril 2025
|
|
NCT02416388
|
Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial (BIG-1)
|
En recrutement
|
10 avril 2025
|
|
NCT03017573
|
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE)
|
En recrutement
|
10 avril 2025
|
|
NCT02355379
|
Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi (ADAGE)
|
En recrutement
|
10 avril 2025
|
|
NCT03246841
|
Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes. (TUMOSPEC)
|
En recrutement
|
10 avril 2025
|
|
NCT03774732
|
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)
|
En recrutement
|
10 avril 2025
|
|
NCT03830788
|
Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy (TEMPOS)
|
En recrutement
|
10 avril 2025
|
|
NCT04290663
|
Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy (INTERMEDIATE)
|
En recrutement
|
10 avril 2025
|
|
NCT04720729
|
Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study (MONDRIAN)
|
En recrutement
|
10 avril 2025
|
|
NCT04790682
|
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer (LIBERTYLUNG)
|
En recrutement
|
10 avril 2025
|
|
NCT04823377
|
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. (PACT-01)
|
En recrutement
|
10 avril 2025
|
|
NCT05354765
|
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA (ALCYTA)
|
En recrutement
|
10 avril 2025
|
|
NCT05088395
|
Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 (ALCINA4)
|
En recrutement
|
10 avril 2025
|
|
NCT05296746
|
Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer (RIBOLARIS)
|
En recrutement
|
10 avril 2025
|
|
NCT05475366
|
Pilot Study of Personalized First-line Chemotherapy Choice for Patients With Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign) (PACsign)
|
En recrutement
|
10 avril 2025
|
|
NCT05439005
|
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study. (OFOBA)
|
En recrutement
|
10 avril 2025
|
|
NCT05486182
|
Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Patients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy (ESTROTIMP)
|
En recrutement
|
10 avril 2025
|
|
NCT05634395
|
Digital Phenotyping (Physical Activity, Sleep) in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment (GrannyFit)
|
En recrutement
|
10 avril 2025
|
|
NCT05441163
|
ProActIF-01 Trial: Randomized Study of Evaluation of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Lung or Digestive Cancers (ProActIF-01)
|
En recrutement
|
10 avril 2025
|
|
NCT05116475
|
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases (ALADDIN)
|
En recrutement
|
10 avril 2025
|
|
NCT05100862
|
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)
|
En recrutement
|
10 avril 2025
|
|
NCT05955170
|
Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II (TUC-TOC)
|
En recrutement
|
10 avril 2025
|
|
NCT06084936
|
A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE)
|
En recrutement
|
10 avril 2025
|
|
NCT06162351
|
A Phase II Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (TOPOLOGY)
|
En recrutement
|
10 avril 2025
|
|
NCT06175390
|
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II Trial (SKYLINE)
|
En recrutement
|
10 avril 2025
|
|
NCT03328078
|
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
|
En recrutement
|
10 avril 2025
|
|
NCT06275737
|
Trimodal Peri Operative Prehabilitation for Upper Oesogastric and Pancreatic Cancer: A Multicenter, Two-cohort, Open-label, Single-arm POP-UP GERCOR Study (POP-UP)
|
En recrutement
|
10 avril 2025
|
|
NCT06195709
|
ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients (ECLECTIC)
|
En recrutement
|
10 avril 2025
|
|
NCT05794906
|
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer (ARASTEP)
|
En recrutement
|
10 avril 2025
|
|
NCT05232916
|
A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (FLAMINGO-01)
|
En recrutement
|
10 avril 2025
|
|
NCT06284122
|
A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma (MorningLyte)
|
En recrutement
|
10 avril 2025
|
|
NCT05939414
|
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC) (PSMA-DC)
|
En recrutement
|
10 avril 2025
|
|
NCT06349512
|
68Ga-FAPI-46 PET/CT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Triple-negative Breast Cancer (FAP-IT)
|
En recrutement
|
10 avril 2025
|
|
NCT05512364
|
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
|
En recrutement
|
10 avril 2025
|
|
NCT06150027
|
A Randomized Comparative Prospective Multicenter Study of the Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers (PALLU)
|
En recrutement
|
10 avril 2025
|
|
NCT05731661
|
Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase (AFTERGYN)
|
En recrutement
|
10 avril 2025
|
|
NCT06356129
|
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) (GOLSEEK-1)
|
En recrutement
|
10 avril 2025
|
|
NCT06459791
|
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Biological Avatar: Proof-of-concept Study (AVATAR)
|
En recrutement
|
10 avril 2025
|
|
NCT05870579
|
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative and Gastrin Releasing Peptide Receptor Positive Advanced Breast Cancer Experiencing Early Relapse From (Neo)Adjuvant Endocrine Therapy or Who Have Progressed on Endocrine Therapy in Combination With a CDK4/6 Inhibitor for Advanced Disease
|
En recrutement
|
10 avril 2025
|
|
NCT06116136
|
Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer
|
En recrutement
|
10 avril 2025
|
|
NCT06558604
|
A Phase II, Multicenter, Open-label Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma (GLOASIS)
|
En recrutement
|
10 avril 2025
|
|
NCT05973864
|
A Phase II Study to Evaluate CAPecitabine Plus Pembrolizumab as Post-operative Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Chemo-immunotherapy (CAPPA)
|
En recrutement
|
27 mars 2025
|
|
NCT03622333
|
Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)
|
En recrutement
|
07 août 2024
|
|
NCT03275311
|
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008 (ESME-MBC)
|
En recrutement
|
20 mars 2023
|
|
NCT03848052
|
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015
|
En recrutement
|
05 novembre 2022
|